EV Insights: Voices from Exosomes Europe

Dr. Tali Kizhner, Research and Development Director of NurExone Biologic Ltd., is driving innovation in regenerative medicine with exosome-based therapies targeting central nervous system injuries. With over 15 years of experience in biopharma advancements, she introduces ExoPTEN, a groundbreaking drug candidate for spinal cord injury repair, and shares her vision for overcoming clinical challenges in the extracellular vesicle field. Highlighting a role for AI and advanced technologies in accelerating development, Dr. Kizhner’s presentation at Exosomes Europe will showcase NurExone’s pioneering use of exosomes for siRNA delivery—a bold approach with the potential to transform millions of lives.

Dive into the groundbreaking innovations of AGS Therapeutics as Manuel Vega, CEO and co-founder, shares insights into the revolutionary potential of microalgae extracellular vesicles (MEVs). From transforming drug delivery systems to addressing unmet medical needs in ophthalmology, bowel diseases, and beyond, this interview explores how MEVs are reshaping the landscape of biomedicine. Discover the science, vision, and passion driving AGS Therapeutics forward. Read the full interview to learn how MEVs could redefine patient care and drug development.

Explore how Professor Bernd Giebel, researcher at University Hospital Essen and co-founder of Exosla, is transforming therapeutics through extracellular vesicles. In this interview, Bernd reveals his journey from stem cell biology to exosome innovation, including a breakthrough Graft-versus-Host Disease treatment. He discusses strategies to overcome production heterogeneity through immortalisation and clonal expansion, emphasising that "quality matters" in advancing exosome therapeutics. Don't miss his insights at Exosomes Europe, where he'll connect with industry experts to accelerate the clinical translation of these game-changing therapies.

Discover how Spencer Marsh, Chief Scientific Officer at The Tiny Cargo Company, is revolutionising drug delivery through milk-derived exosomes. In this exclusive interview, Spencer shares his journey from cardiac tissue research to developing shelf-stable, orally-administered therapeutics. Learn about the company's innovative approach to loading pharmaceuticals into milk exosomes, the challenges facing the EV industry, and why exosome therapies may soon replace traditional cell therapies. Don't miss Spencer's insights at Exosomes Europe 2025, where he'll discuss manufacturing innovations and the untapped potential of alternative exosome sources.